Evidence map›Paper›PMID 22448923›Full record

ArticleLeukemia & lymphoma2012

Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.

Rathi N Pillai, Lisa S Chen, Mary L Ayres, Billie J Nowak, Michael W Thomas, Elizabeth J Shpall, Michael J Keating, Varsha Gandhi

Abstract read
In one paragraph

Article in Leukemia & lymphoma, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rathi N PillaiDepartment of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230-1429, USA.
Lisa S Chen
Mary L Ayres
Billie J Nowak
Michael W Thomas
Elizabeth J Shpall
Michael J Keating
Varsha Gandhi
The University of Texas MD Anderson Cancer Center · USEmory University · USLeukemia Research Foundation · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERRY, DONALD A · 2009 to 2011
$1.5M
NCI NIH HHS CA136411NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA136411
6 · The paper itself

Abstract

Survival of chronic myelogenous leukemia (CML) cells is dependent on BCR-ABL kinase, the activity of which is contingent on the level of BCR-ABL protein and the availability of adenosine triphosphate (ATP). We hypothesized that 8-amino-adenosine (8-amino-Ado)-mediated reduction in cellular ATP level and inhibition of mRNA synthesis leading to a decrease in protein level would result in a multifaceted targeting of BCR-ABL. Using K562 cells, we demonstrated that there was a dose- and time-dependent increase in 8-amino-ATP accompanied by a > 95% decline in the endogenous ATP pool. In parallel, 8-amino-Ado inhibited RNA synthesis and resulted in a depletion of BCR-ABL transcript. Consistent with this, BCR-ABL and ABL protein levels were also decreased. These effects were associated with the initiation of cell death as visualized by poly(ADP-ribose) polymerase (PARP) cleavage, decreased clonogenicity and greater than additive interaction with imatinib. In imatinib-sensitive and -resistant KBM5 cells, 8-amino-Ado treatment augmented the imatinib effect on growth inhibition.

Indexed as

AdenosineAdenosine TriphosphateAntineoplastic AgentsApoptosisBenzamidesCell ProliferationCell SurvivalDrug Resistance, NeoplasmFusion Proteins, bcr-ablGene Expression Regulation, LeukemicHumansImatinib MesylateK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositivePiperazinesProtein Kinase Inhibitors8-aminoadenosineAdenosineAdenosine TriphosphateAntineoplastic AgentsBenzamidesFusion Proteins, bcr-ablImatinib MesylatePiperazinesProtein Kinase InhibitorsPyrimidines

Identifiers

PMID22448923
PMCPMC5648543
OpenAlexW2122744674

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.